Global Wearable Injectors Industry

Global Wearable Injectors Industry

  • April 2021 •
  • 207 pages •
  • Report ID: 5800065 •
  • Format: PDF
Abstract:
- Global Wearable Injectors Market to Reach $9.2 Billion by 2027
- Amid the COVID-19 crisis, the global market for Wearable Injectors estimated at US$4.8 Billion in the year 2020, is projected to reach a revised size of US$9.2 Billion by 2027, growing at aCAGR of 9.7% over the period 2020-2027. On-Body injectors, one of the segments analyzed in the report, is projected to record 9.5% CAGR and reach US$6.7 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Off-Body injectors segment is readjusted to a revised 10.2% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $1.4 Billion, While China is Forecast to Grow at 9.1% CAGR
- The Wearable Injectors market in the U.S. is estimated at US$1.4 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2027 trailing a CAGR of 9.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 9% and 7.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.8% CAGR.

- Select Competitors (Total 43 Featured) -
  • Amgen, Inc.
  • Becton, Dickinson and Company
  • Bespak Europe Ltd.
  • Enable Injections, Inc.
  • Insulet Corporation
  • Medtronic PLC
  • Sensile Medical AG
  • Tandem Diabetes Care, Inc.
  • United Therapeutics Corporation
  • Valeritas, Inc.